There are 420 therapies in development to treat neurological disorders such as multiple sclerosis and Parkinson’s disease that affect an estimated 50-million Americans, according to a new report from PhRMA and the Epilepsy Foundation.
Many of the experimental treatments are being tested to treat rare diseases, but about 40% of the 420 treatments are being tested to treat chronic pain, epilepsy and Alzheimer’s disease. Less common areas of focus include spasticity, spinal cord injuries and Huntington’s disease.
The drugs are in human clinical trials or being reviewed by the FDA.
